Recorded fact · drug.trial_access

drug.trial_access for apalutamide

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact f2cc4047 resolves to.

The record

Fact id	`f2cc404790f6c26a530e0eca`
Entity	drug: apalutamide
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "APALUTAMIDE",
 "recruitingInterventionalCount": 39,
 "notYetRecruitingCount": 7,
 "byPhase": {
  "PHASE2": 14,
  "PHASE3": 14,
  "PHASE1": 5,
  "NA": 3,
  "PHASE1/PHASE2": 3
 },
 "trials": [
  {
   "nctId": "NCT07745361",
   "briefTitle": "Study of Oral MRT-2359 With Apalutamide in Prostate Cancer",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Monte Rosa Therapeutics, Inc",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-08-18",
   "conditions": [
    "Castration-Resistant Prostate Cancer (CRPC)",
    "Castration-Resistant Prostate Cancer",
    "Prostate Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07745361"
  },
  {
   "nctId": "NCT07751133",
   "briefTitle": "Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "University College, London",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2026-08-28",
   "conditions": [
    "Prostate Cancer",
    "mHSPC",
    "mCRPC"
   ],
   "countries": [
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07751133"
  },
  {
   "nctId": "NCT05818683",
   "briefTitle": "A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Janssen Research & Development, LLC",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2023-04-26",
   "conditions": [
    "Metastatic Castration-resistant Prostate Neoplasms",
    "Metastatic Hormone-sensitive Prostate Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05818683"
  },
  {
   "nctId": "NCT06095089",
   "briefTitle": "A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Janssen Research & Development, LLC",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2023-11-01",
   "conditions": [
    "Prostatic Neoplasms"
   ],
   "countries": [
    "United States",
    "Australia",
    "China",
    "France",
    "Japan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06095089"
  },
  {
   "nctId": "NCT06931340",
   "briefTitle": "Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Alliance for Clinical Trials in Oncology",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2025-12-01",
   "conditions": [
    "Castration-Sensitive Prostate Carcinoma",
    "Metastatic Prostate Adenocarcinoma",
    "Stage IVB Prostate Cancer AJCC v8"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06931340"
  },
  {
   "nctId": "NCT07611110",
   "briefTitle": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-19",
   "startDate": "2026-05-04",
   "conditions": [
    "Metastatic Castration-resistant Prostate Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Austria",
    "Belgium",
    "Brazil",
    "Canada",
    "China",
    "Finland",
    "France",
    "Germany"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07611110"
  },
  {
   "nctId": "NCT07783282",
   "briefTitle": "A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Astellas Pharma Global Development, Inc.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-16",
   "startDate": "2026-09-25",
   "conditions": [
    "Prostate Cancer"
   ],
   "countries": [
    "Bulgaria"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07783282"
  },
  {
   "nctId": "NCT05534646",
   "briefTitle": "Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Edwin Posadas, MD",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-05",
   "startDate": "2023-12-27",
   "conditions": [
    "Castration-resistant Prostate Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05534646"
  },
  {
   "nctId": "NCT05647564",
   "briefTitle": "PET/CT Characterization of Treatment Resistance",
   "phase": [
    "NA"
   ],
   "leadSponsor": "University of Wisconsin, Madison",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-01",
   "startDate": "2023-03-06",
   "conditions": [
    "Prostate Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05647564"
  },
  {
   "nctId": "NCT07002320",
   "briefTitle": "Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Institute of Cancer Research, United Kingdom",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-08",
   "startDate": "2025-04-28",
   "conditions": [
    "Metastatic Castrate-Resistant Prostate Cancer (mCRPC)"
   ],
   "countries": [
    "Switzerland",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07002320"
  },
  {
   "nctId": "NCT04423211",
   "briefTitle": "Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "ECOG-ACRIN Cancer Re
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: fcfd9b256606ce7e3365e55602448fdf6e00fb2676323d5613dd42cd1370c070.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.